At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 13,885 enrolled
Drug / intervention
Ticagrelor +1 moredrug
Likely dose
Ticagrelor 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
In Brief
A Phase 3 clinical trial evaluating Ticagrelor and Clopidogrel for Peripheral Artery Disease. Completed, enrolled 13,885 participants across 776 sites in 28 countries.
Detailed Summary
The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Artery Disease
CountriesArgentina, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Hungary, Italy, Japan, Mexico, Netherlands, Philippines, Poland, Romania, Russia, Slovakia, South Korea, Spain, Sweden, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, United States, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartDec 2012
Primary CompletionSep 2016
TodayJul 2026
First PostedNov 26, 2012
Enrollment StartDec 4, 2012
Primary CompletionSep 26, 2016
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.6 years ago
Interventions
Ticagrelordrug
Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
Clopidogreldrug
Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets